EFFICIENCY AND SAFETY OF CHEMOTHERAPY REGIMEN WITH SQ109 IN THOSE SUFFERING FROM MULTIPLE DRUG RESISTANT TUBERCULOSIS

The objective of the study: to assess efficiency and safety of SQ109 used within standard treatment regimens for multiple drug resistant tuberculosis (MDR TB)

Subjects and Methods A multi-center, double, blind, randomized, placebo-controlled study was conducted in two parallel groups from September 21, 2012 to September 30, 2016, in 6 research centers located in 5 cities of the Russian Federation

Main results 1 Cessation of bacillary excretion confirmed by cultures on liquid media by the end of the 6th month of the intensive phase of chemotherapy in pulmonary MDR TB patients receiving SQ109 was observed confidently more often versus treatment regimens containing only existing anti-tuberculosis drugs: both for ITT population (610% versus 429%, p = 00412), and PP population (797% versus 614%, p = 00486) 2 There were no statistically significant differences in the achievement of sputum conversion between the groups, but by the end of the 8th week, the sputum converted in 52% of patients in the group treated with SQ109 versus 38% in the group taking a placebo The median time of bacillary excretion cessation confirmed by culture on liquid media in SQ109 group made 56 days, while in the placebo group it was 84 days 3 Use of SQ109 along with basic chemotherapy for pulmonary MDR TB did not result in the higher frequency of adverse events, worsening of their severity, development of new variants of adverse events compared to the basic anti-tuberculosis treatment of this group of patients in combination with placebo 4 Results of the study allow concluding that SQ109 is an effective drug, satisfactory tolerated (compatible with tolerability of placebo) being a part of integral etiotropic chemotherapy of pulmonary MDR TB patients

1. Edict no. 109 by RF MoH as of March 21, 2003 On Improvement of TB Control Measures in the Russian Federation. (Version as of 29.10.2009, Epub.) Available at: http://www.consultant.ru/document/ cons_doc_LAW_100829. (Accessed 20.08.2015). (In Russ.)

2. Opredelenie stepeni dostovernosti prichinno-sledstvennoy svyazi «neblagopriyatnaya pobochnaya reaktsiya – lekarstvennoe sredstvo» (klassifikatsiya i metody): metodicheskie rekomendatsii. [Defining the degree of causal relationships between an adverse event and the drug (classification and methods): guidelines]. Federalnaya Sluzhba Po Nadzoru V Sfere Zdravookhraneniya I Sotsialnogo Razvitiya Publ. Moscow, 2008. (Epub.) Available at: http://pandia.ru/text/78/557/9463.php. (Accessed 29.03.2015).

3. Sovershenstvovanie diagnostiki i lecheniya tuberkuleza organov dykhaniya: metodicheskie rekomendatsii. [Improvement of diagnostics and treatment of respiratory tuberculosis: guidelines], Russian Ministry of Health Publ., Moscow, 2014, 47 p.

4. The website of Central Research Institute for Public Health Organization and Informatization, Russian Ministry of Health. (Epub.) Available at: http://mednet. ru/ru/statistika/protivotuberculeznaya-sluzhba.html. (Accessed 01.04.2017). (In Russ.)

5. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. 3rd ed., Moscow, 2015, 68 p. http://roftb.ru/netcat_files/doks2015/3final.pdf

6. Ahuja S.D., Ashkin D., Avendano M. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLos Med., 2012, vol. 9, no. 8, pp. e1001300.

7. Bastos M.L., Hussain H., Weyer K. et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin. Infect. Dis., 2014, vol. 59, no. 10, pp. 1364-1374.

8. Chang K.-Ch., Yew W.-W., Tam Ch.-M., Leung Ch.-Ch. WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis. Antimicrob. Agents Chemother., 2013, vol. 57, no. 9, pp. 4097-4104.

9. Diacon A.H., Donald P.R., Pym A. et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother., 2012, vol. 56, no. 6, pp. 3271-3276.

10. Diacon A.H., Pym A., Grobusch M.P. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med., 2014, vol. 371, no. 8, pp. 723-732.

11. Division of Microbiology and Infection Diseases (DMID) adult toxicity table. Microbiology and Infectious Diseases Clinical Research Policies, Guidance, and Tools. National Institute of Allergy and Infectious Diseases, Bethesda, 2007. Available at: http://www.niaid.nih. gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmid. adulttox.pdf. (Accessed as of 09.07.2013).

12. Gandhi N.R., Nunn P., Dheda K. et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet, 2010, vol. 375, no. 9728, pp. 1830-1843.

13. Ginsberg A.M. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb.), 2010, vol. 90, no. 3, pp. 162-167.

14. Global tuberculosis report 2015. WHO/HTM/TB/2015.22. 2015, 192 p. (Epub.) Availabe at: http://www.who.int/tb/publications/global_report/ru/ (Accessed 01.04.2017).

15. Jia L., Tomaszewski J.E., Hanrahan C. et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol., 2005, vol. 144, no. 1, pp. 80-87.

16. Johnston J.C., Shahidi N.C., Sadatsafavi M., Fitzgerald J.M. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One, 2009, vol. 4, no. 9, pp. e16914.

17. Kurbatova E.V., Cegielski J.P., Lienhardt C. et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir. Med., 2015, vol. 3, no. 3, pp. 201-209.

18. Li K., Schurig-Briccio L.A., Feng X. et al. Multitarget drug discovery for tuberculosis and other infectious diseases. J. Med. Chem., 2014, vol. 57, no. 7, pp. 3126-3139.

19. Li W., Upadhyay A., Fontes F.L. et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, vol. 58, no. 11, pp. 6413-6423.

20. Migliori G.B., Centis R., Lange C. et al. Emerging epidemic of drug-resistant tuberculosis in Europe, Russia, China, South America and Asia: current status and global perspectives. Curr. Opin. Pulm. Med., 2010, vol. 16, no. 3, pp. 171-179.

21. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, WHO, 2010. (Epub.) Available at: http://whqlibdoc.who.int/publications/ 2010/ 9789241599191_eng.pdf?ua=1. (Accessed 29.03.2015).

22. Naranjo С.A., Busto U., Sellers E.M. et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther., 1981, vol. 30, pp. 239-245.

23. Safety of Medicines: а guide to detecting and reporting adverse drug reactions. Geneva, WHO, 2012. 19 p. (Epub.) Available at: http://whqlibdoc.who. int/hq/2002/WHO_EDM_QSM_2002.2.pdf. (Accessed 29.03.2015).

24. Shin S.S., Keshavjee S., Gelmanova I.Y. et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am. J. Respir. Crit. Care Med., 2010, vol. 182, no. 3, pp. 426-432.

25. Sacksteder K.A., Protopopova M., Barry C.E. et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol., 2012, vol. 7, no. 7, pp. 823-837.

26. Tahlan K., Wilson R., Kastrinsky D.B. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2012, vol. 56, pp. 1797-1809.

27. Te Brake L.H., Russel F.G., van den Heuvel J.J. et al. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. Tuberculosis (Edinb.), 2016, no. 1 (96), pp. 150-157.

28. Treatment of tuberculosis: guidelines. 4th ed. (WHO/HTM/TB/2009.420) Geneva, WHO, 2009. (Epub.) Available at: http://www.who.int/tb/publications/2009/ who_htm_tb_2009_420_beforeprint.pdf. (Accessed 29.03.2015)

29. Wallis R.S., Jakubiec W., Mitton-Fry M. et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One, 2012, vol. 7, no. 1, pp. e30479.

30. Wu S., Zhang Y., Sun F. et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am. J. Ther., 2016, vol. 23, no. 3, pp. e521-530.

31. Zumla A., Chakaya J., Centis R. et al. Tuberculosis treatment and management – an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir. Med., 2015, vol. 3, no. 3, pp. 220-234.